Back to search results

Medilepsy® App for Epilepsy Medication Adherence

This study is looking at whether an AI-powered version of the Medilepsy® app can help young people with epilepsy better manage their medication and prepare for transitioning to adult care. You might be able to join if you are 14-24 years old, have epilepsy, take anti-seizure medicine, and are part of an underserved community (like a racial or ethnic group underrepresented in healthcare, or have low income). The study will compare the AI-enhanced Medilepsy® Chatbot to a standard version of the app. Researchers want to see if the AI version improves how well you take your medication over 3-6 months.

Study design
This study plans to enroll 200 participants and compares two versions of the Medilepsy® app: one with AI and one without.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main effects of the app will be measured at 3-6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07445074

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Recruiting
NAAges 14–24InterventionalSupportive care
University of Central Florida
~200 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Medilepsy® Chatbot AI-EnhancedMedilepsy® Chatbot Standard

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Examine the effect of Medilepsy® with and without responsible AI design on medication adherence.
Measured over 3-6 months

Conditions

Epilepsy
Seizure

Explore related trials

Seizure Disorder

Where it's being run

2 sites across 1 states
Florida2

Study leadership

  • Michelle Tall, PhD, RN, FAES · PRINCIPAL_INVESTIGATOR · University of Central Florida

Who to contact

Michelle Tall, PhD, RN, FAES
[email protected]
4077970555
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with epilepsy
Currently prescribed anti-seizure medicine (ASMs)
Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
Are between 18-24 years old and able to provide informed consent
Able to read, speak, and write in English
Resides in Florida
Receive outpatient medical services

Exclusion

They do not own a mobile device with internet access.
They have a history of severe intellectual disability.
They are unable to operate a mobile device (keyboard or touchscreen).
Reside in an in-patient setting.
Adults unable to consent.
Pregnant women (excluded because pregnancy is not relevant to the study focus).
Prisoners.

What this trial measures

  • Examine the effect of Medilepsy® with and without responsible AI design on medication adherence.3-6 months

    Participants will demonstrate significant improvement in medication adherence measured by Medication adherence rate (MAR) formula: The average number of missed medications. Adherence Rate (%) = (Number of prescribed ASM doses taken / Number of prescribed ASM doses scheduled) × 100.